December 10, 2025
Imaging Biometrics, Ltd
("IBAI" or the "Company")
Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetric™
Imaging Biometrics (IB), a leader in advanced neuroimaging solutions, announces an amendment to its distribution agreement with GE HealthCare, expanding access to two innovative offerings: FTB Express maps and QSMetric.
The agreement already includes IB Neuro and Delta T1 maps, widely adopted together to assist clinicians in diagnosing, planning, and monitoring treatment response for brain tumor patients. Delta T1 maps provide rapid, objective delineation of contrast-enhancing regions, while IB Neuro generates standardized (quantitative) MR DSC perfusion images of relative cerebral blood volume (sRCBV), which eliminates manual tissue normalization. These outputs serve as inputs for Fractional Tumor Burden (FTB) maps, which deliver automated visualization of tumor versus non-tumor tissue and treatment effects within enhancing regions. FTB Express accelerates this process, enabling clinicians to quickly access actionable insights for patient care.
QSMetric is a patented quantitative susceptibility mapping software that processes gradient echo brain images to visualize tissue structures and measure susceptibility values. This capability supports a broad range of clinical applications, including targeting for deep brain stimulation (DBS) surgery, neurodegenerative disease assessment, multiple sclerosis, and more.
Katie Anderson, Global MR Visualization Product Manager at GE HealthCare, said, "We are excited to expand our collaboration with Imaging Biometrics to enable access for our customers to these clinically important capabilities."
--ENDS-
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
| Imaging Biometrics Ltd Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda Tel: 020 7469 0930 |
| AlbR Capital Limited (Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797 |
About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of Imaging Biometrics, Ltd, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on X @ImgBiometrics.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.